Gemcitabine and leflunomide for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer that has spread and cannot be removed by surgery.
- You are 18 years or older.
- You are able to take pills by mouth.
- You are not pregnant and agree to use birth control during and for a time after treatment.
- You have not had chemotherapy or other cancer treatment in the last 3 weeks.
- You do not have active infections like tuberculosis, HIV, or hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
This trial tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) for people with pancreatic cancer that has spread to other parts of the body. It is for those whose tumors have specific genetic changes (in the SWI/SNF genes) and have only had one prior treatment that was not immunotherapy.
This trial tests gemcitabine chemotherapy in people with metastatic pancreatic cancer who cannot take FOLFIRINOX. It aims to see how well gemcitabine works based on a specific tumor marker called GemCore.
This trial tests a new drug, LM-302, combined with gemcitabine for people with a specific type of advanced pancreatic cancer that has not responded to or stopped working on first-line treatment. The goal is to see if the combination is safe and effective.
Hear when a new Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.